EA201400526A1 - Смесь связанного триптофана в составе пептидов и связанного триптофана в составе полипептидов - Google Patents

Смесь связанного триптофана в составе пептидов и связанного триптофана в составе полипептидов

Info

Publication number
EA201400526A1
EA201400526A1 EA201400526A EA201400526A EA201400526A1 EA 201400526 A1 EA201400526 A1 EA 201400526A1 EA 201400526 A EA201400526 A EA 201400526A EA 201400526 A EA201400526 A EA 201400526A EA 201400526 A1 EA201400526 A1 EA 201400526A1
Authority
EA
Eurasian Patent Office
Prior art keywords
composition
polypeptides
peptides
triptophane
triptophan
Prior art date
Application number
EA201400526A
Other languages
English (en)
Other versions
EA029869B1 (ru
Inventor
Синдерелла Кристина Герхардт
Люппо Эденс
Original Assignee
ДСМ АйПи АССЕТС Б.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ДСМ АйПи АССЕТС Б.В. filed Critical ДСМ АйПи АССЕТС Б.В.
Publication of EA201400526A1 publication Critical patent/EA201400526A1/ru
Publication of EA029869B1 publication Critical patent/EA029869B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
    • A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
    • A23J1/08—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from eggs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
    • A23J3/00—Working-up of proteins for foodstuffs
    • A23J3/30—Working-up of proteins for foodstuffs by hydrolysis
    • A23J3/32—Working-up of proteins for foodstuffs by hydrolysis using chemical agents
    • A23J3/34—Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
    • A23J3/00—Working-up of proteins for foodstuffs
    • A23J3/30—Working-up of proteins for foodstuffs by hydrolysis
    • A23J3/32—Working-up of proteins for foodstuffs by hydrolysis using chemical agents
    • A23J3/34—Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes
    • A23J3/341—Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes of animal proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/04—Alpha- or beta- amino acids
    • C12P13/22—Tryptophan; Tyrosine; Phenylalanine; 3,4-Dihydroxyphenylalanine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01017—Lysozyme (3.2.1.17)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

Настоящее изобретение касается композиции, которая включают триптофан, где от 10 до 90%, предпочтительно от 20 до 80% триптофана присутствует в виде свободного триптофана или связанного триптофана в составе пептидов, и от 10 до 90%, предпочтительно от 20 до 80% триптофана присутствует в виде связанного триптофана в составе полипептидов.
EA201400526A 2008-04-29 2009-04-27 Способ получения обогащенного триптофаном гидролизата лизоцима и композиция, содержащая гидролизат EA029869B1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08155315 2008-04-29

Publications (2)

Publication Number Publication Date
EA201400526A1 true EA201400526A1 (ru) 2014-12-30
EA029869B1 EA029869B1 (ru) 2018-05-31

Family

ID=39811461

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201400526A EA029869B1 (ru) 2008-04-29 2009-04-27 Способ получения обогащенного триптофаном гидролизата лизоцима и композиция, содержащая гидролизат
EA201001711A EA021506B1 (ru) 2008-04-29 2009-04-27 Композиция для увеличения отношения trp/lnaa в плазме крови и способ ее получения

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201001711A EA021506B1 (ru) 2008-04-29 2009-04-27 Композиция для увеличения отношения trp/lnaa в плазме крови и способ ее получения

Country Status (10)

Country Link
US (2) US8802088B2 (ru)
EP (1) EP2268157B1 (ru)
JP (1) JP5626807B2 (ru)
KR (1) KR101698216B1 (ru)
CN (1) CN102076228B (ru)
BR (1) BRPI0911907B8 (ru)
EA (2) EA029869B1 (ru)
ES (1) ES2550463T3 (ru)
PL (1) PL2268157T3 (ru)
WO (1) WO2009133055A1 (ru)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2382910T3 (es) 2006-11-02 2012-06-14 Dsm Ip Assets B.V. Uso de hidrolizados de lisozima que contienen triptófano
CN102076222B (zh) * 2008-04-29 2014-04-09 帝斯曼知识产权资产管理有限公司 包含碳水化合物和含色氨酸的肽的组合物
KR101698216B1 (ko) * 2008-04-29 2017-01-19 디에스엠 아이피 어셋츠 비.브이. 펩타이드-결합된 트립토판과 폴리펩타이드-결합된 트립토판의 혼합물
CN103153326B (zh) * 2010-10-05 2015-08-19 帝斯曼知识产权资产管理有限公司 含有色氨酸的肽
PL2701716T3 (pl) 2011-04-28 2018-02-28 Dsm Ip Assets B.V. Hydrolizaty białkowe jako środki do przezwyciężania uzależnień
US10194674B2 (en) 2011-09-01 2019-02-05 John C. Gilkey Nutritional compositions
JP2013159591A (ja) * 2012-02-08 2013-08-19 Morinaga Milk Ind Co Ltd 多動性抑制剤
CN104334037B (zh) * 2012-11-02 2019-02-22 帝斯曼知识产权资产管理有限公司 富含色氨酸的蛋白水解产物的用途
EP3082837B1 (en) * 2013-12-18 2020-09-09 DSM IP Assets B.V. Compositions comprising lysozyme hydrolysate for use in keratin-containing tissue
CA2995395C (en) * 2015-08-31 2024-04-16 Nutramax Laboratories, Inc. Compositions comprising magnolia, phellodendron, theanine and/or whey protein
US10591221B1 (en) 2017-04-04 2020-03-17 Mainstream Engineering Corporation Advanced cooling system using throttled internal cooling passage flow for a window assembly, and methods of fabrication and use thereof
JP7139727B2 (ja) * 2018-06-29 2022-09-21 キリンホールディングス株式会社 運動制御機能および運動学習機能向上用組成物
NL2022627B1 (en) 2019-02-22 2020-08-31 Newtricious Bv Lysozyme hydrolysate for proactive inhibitory control and for attention
JP7428480B2 (ja) * 2019-06-06 2024-02-06 雪印メグミルク株式会社 睡眠改善用組成物及び組成物を含む食品、医薬品、飼料
CA3212435A1 (en) * 2021-03-15 2022-09-22 Lara Nyman Nutritional composition for improving sleep
WO2024204250A1 (ja) * 2023-03-29 2024-10-03 株式会社明治 ドーパミン放出量増強剤、運動制御機能改善剤、運動学習機能改善剤及び活動意欲改善剤

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02279700A (ja) * 1989-04-19 1990-11-15 Asahi Chem Ind Co Ltd 高トリプトファン含有ペプチド
FR2657013B1 (fr) * 1990-01-18 1992-05-15 Medgenix Group Sa Composition dietetique a base de polypeptides et acides amines.
KR100796853B1 (ko) * 2000-12-06 2008-01-22 캄피나 쥐벨 베.붸. 과량 트립토판 함유 펩티드의 제조방법
JP4221231B2 (ja) 2002-02-28 2009-02-12 株式会社ファーマフーズ 抗菌組成物、その製造方法及び該抗菌組成物を含有する抗菌剤
CN1968691B (zh) 2004-04-19 2010-12-29 麒麟麦酒株式会社 用于通过葡糖异生作用加速酒精代谢或从疲劳恢复的组合物
CN101022737B (zh) 2004-07-22 2012-08-15 格罗伯斯卵类科学有限公司 抗高血压的功能性食品
EP1685764A1 (en) * 2005-01-27 2006-08-02 Globus Egg Sciences B.V. Anti-hypertensive functional food products
US7618669B2 (en) * 2005-06-01 2009-11-17 Mead Johnson Nutrition Company Low-lactose partially hydrolyzed infant formula
ES2382910T3 (es) * 2006-11-02 2012-06-14 Dsm Ip Assets B.V. Uso de hidrolizados de lisozima que contienen triptófano
KR101698216B1 (ko) * 2008-04-29 2017-01-19 디에스엠 아이피 어셋츠 비.브이. 펩타이드-결합된 트립토판과 폴리펩타이드-결합된 트립토판의 혼합물
CN102076222B (zh) * 2008-04-29 2014-04-09 帝斯曼知识产权资产管理有限公司 包含碳水化合物和含色氨酸的肽的组合物

Also Published As

Publication number Publication date
KR101698216B1 (ko) 2017-01-19
WO2009133055A1 (en) 2009-11-05
US9770493B2 (en) 2017-09-26
EA201001711A1 (ru) 2011-06-30
PL2268157T3 (pl) 2015-12-31
JP5626807B2 (ja) 2014-11-19
US20150037313A1 (en) 2015-02-05
US20110110919A1 (en) 2011-05-12
US8802088B2 (en) 2014-08-12
CN102076228A (zh) 2011-05-25
BRPI0911907B8 (pt) 2021-05-25
EA029869B1 (ru) 2018-05-31
BRPI0911907B1 (pt) 2021-02-02
EP2268157B1 (en) 2015-08-19
EP2268157A1 (en) 2011-01-05
KR20100135319A (ko) 2010-12-24
ES2550463T3 (es) 2015-11-10
JP2011523547A (ja) 2011-08-18
BRPI0911907A2 (pt) 2015-07-28
EA021506B1 (ru) 2015-07-30
CN102076228B (zh) 2016-08-03

Similar Documents

Publication Publication Date Title
EA201001711A1 (ru) Смесь связанного триптофана в составе пептидов и связанного триптофана в составе полипептидов
EA200970132A1 (ru) Аналоги морфолинила и пирролидинила
EA201270528A1 (ru) Композиции цитокинов семейства il-17 и их применение
MX2011013455A (es) Diseño de moleculas de fc de anticuerpo estables y libres de agregacion a traves del diseño de la interfase del dominio de ch3.
TW200719892A (en) Modulators of indoleamine 2,3-dioxygenase and methods of using the same
MX2010008696A (es) Composiciones de proteina estabilizadas.
MX382826B (es) Anticuerpos dkk1 y metodos de uso.
NO20092470L (no) Substituerte diazepanforbindelser som orexinreseptorantagonister
EA200870514A1 (ru) Ацетиленовые гетероарильные соединения
PH12015501848A1 (en) Binding agents
TW200637490A (en) Fertilizer-compatible composition
EA201170295A1 (ru) ИНГИБИТОРЫ сМЕТ
EA200870409A1 (ru) Антагонисты киназы pi3
EA201200850A1 (ru) Фармацевтическая композиция, содержащая олигопептиды
MX2009008104A (es) Hepcidina, antagonistas de hepcidina y metodos de uso.
MY174493A (en) Binding agents
EA201071169A1 (ru) ГИДРОКСИМЕТИЛПИРРОЛИДИНЫ В КАЧЕСТВЕ АГОНИСТОВ АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ β3
MX2009005462A (es) Analogos de 7,8-saturados-4,5-epoxi-morfinano.
TN2010000169A1 (en) Molecules and methods for modulating complement component
EA201101478A1 (ru) Композиции и способы модулирования связывания ретинола с ретинолсвязывающим белком 4 (rbp4)
EA200870465A1 (ru) Антагонисты рецептора il-8
EA201291180A1 (ru) Композиции и способы применения терапевтических антител против белка, родственного рецептору липопротеинов низкой плотности 6 (lrp6)
EA200870515A1 (ru) Моноциклические гетероарильные соединения
EA200970981A1 (ru) Пептидная смесь в качестве стабилизатора вина
EA201201623A1 (ru) Лечение диабета 2 типа

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM